112193-41-6

Usage

Uses

Used in Pharmaceutical Synthesis:
5-BROMOPYRIDINE-3-CARBOHYDRAZIDE is used as a key reactant for the synthesis of various pharmaceutical drugs. Its unique chemical structure allows it to be a versatile building block in the development of new medications with potential therapeutic applications.
Used in Agrochemical Synthesis:
In the agrochemical industry, 5-BROMOPYRIDINE-3-CARBOHYDRAZIDE is used as a precursor in the production of various agrochemicals. Its reactivity and functional groups make it suitable for the creation of compounds that can be used in crop protection and pest management.
Used in Scientific Research:
5-BROMOPYRIDINE-3-CARBOHYDRAZIDE is utilized as a research chemical in laboratories, where it is employed to study its properties, reactivity, and potential applications in various chemical reactions. Its use in research helps to expand the understanding of pyridine carbazides and their role in organic chemistry.
Note: Since the provided materials do not specify different applications in various industries, the uses are generalized based on the information given. If there are specific applications in different industries, they can be added following the format provided in the example.

InChI:InChI=1/C6H6BrN3O/c7-5-1-4(2-9-3-5)6(11)10-8/h1-3H,8H2,(H,10,11)

Upstream product

• 29681-44-5 5-bromo-3-pyridine carboxylic acid methyl ester 
• 20986-40-7 ethyl 5-bromo-3-pyridinecarboxylate 
• 39620-02-5 5-bromonicotinoyl chloride 
• 20826-04-4 5-bromo-3-pyridinecarboxylic acid 
• 98555-51-2 5-Bromo-pyridine-2,3-dicarboxylic acid 

Downstream Products

• 126581-82-6 1-(5-Bromo-pyridine-3-carbonyl)-pyrrolidine-2-carboxylic acid 
• 1201594-83-3 4-[5-(5-bromopyridin-3-yl)-1,3,4-thiadiazol-2-yl]benzonitrile 
• 1198081-97-8 (E)-5-bromonicotinic acid [1-(4-chlorophenyl)methylidene]hydrazide 
• 1464794-49-7 (E)-2-(5-bromopyridin-3-yl)-5-(3,4,5-trimethoxystyryl)-1,3,4-oxadiazole 
• 1272355-45-9 5-(5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)-1,3,4-oxadiazol-2-amine 
• 1039851-68-7 5-(5-bromopyridin-3-yl)-1,3,4-oxadiazol-2-amine 
• 118420-37-4 (E)-N-[4-(4-Benzhydryl-piperazin-1-yl)-butyl]-3-(5-bromo-pyridin-3-yl)-acrylamide 
• 113118-81-3 5-bromopyridine-3-carbaldehyde 

Relevant academic research and scientific papers

TRIAZOLE AGONISTS OF THE APJ RECEPTOR

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures where the definitions of the variables are provided herein.

Synthesis, biologicalevaluation, and molecular modeling of (E)-2-aryl-5-styryl-1,3,4-oxadiazolederivatives as acetylcholine esterase inhibitors

A library of 2,5-disubstituted 1,3,4-oxadiazole derivatives of (E)-2-aryl-5-(3,4,5-trimethoxystyryl)-1,3,4-oxadiazoles 4(a-o) and (E)-2-aryl-5-(2-benzo[d][1,3]dioxol-5-yl)vinyl)-1,3,4-oxadiazoles 5(a-q) were synthesized and evaluated for their in vitro acetylcholinesterase (AChE) inhibitory activity. All the synthesized compounds exhibited moderate to good inhibitory activity toward the AChE enzyme. Among the oxadiazole derivatives examined, compounds 4a, 4g, 5c, and 5m (IC50 values of 24.89, 13.72, 37.65, and 19.63 μM, respectively) were found to be promising inhibitors of AChE. Molecular protein-ligand docking studies were examined for these compounds using GOLD docking software and their binding conformations were determined and the simultaneous interactions mode was also established for the potent derivatives. Springer Science+Business Media 2013.

SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS

The present invention relates to compounds described herein Formula (I) and pharmaceutical acceptable salts thereof, which modulate the activity of calcium release- activated calcium (CRAC) channel. The invention also describes the compounds of Formula (I)and pharmaceutical compositions containing such compounds thereof for treating, managing, and/or lessening the severity of diseases, disorders, syndromes or conditions associated with the modulation of calcium release-activated calcium (CRAC) channel.

QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS

A compound of formula (I) wherein A, X, Y, Z, R1 and R24 are described herein. The compounds are useful as inhibitors of potassium channel function and in the treatment and prevention of arrhythmia, IKur-associated disorders, and other disorders mediated by ion channel function.

Acrylamide derivatives as antiallergic agents. 2. Synthesis and structure-activity relationships of N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3-(3-pyridyl)acrylamides

A new series of 3-(3-pyridyl)acrylamides 16, 17, 19, and 26, and 5-(3-pyridyl)-2,4-pentadienamides 20-25 were prepared and evaluated for their antiallergic activity. Several of these compounds exhibited more potent inhibitory activities than the parent compounds 1a [(E)-N-[4 [4-(diphenylmethyl)-1-piperazinyl]butyl]-3-(3-pyridyl)acrylamide] against the rat passive cutaneous anaphylaxis (PCA) reaction and the enzyme 5-lipoxygenase. Particularly, 4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3-(6-methyl-3-pyridyl)acrylamide (17p) showed an ED50 value of 3.3 mg/kg po in the rat PCA test, which was one-fifth of ketotifen and oxatomide. As compared with ketotifen and oxatomide, compound 17p (AL-3264) possessed a better balance of antiallergic properties due to inhibition of chemical mediator release, inhibition of 5-lipoxygenase, and antagonism of histamine.